April 23, 2013 | Inside Counsel
IP: India, generics and the impact of Novartis’ failed Gleevec claimsIndia has earned its reputation as the worlds pharmacy because it suppliesprimarily in the form of genericsmuch of the affordable medicine needed by countries in the developing world.
By Jake Holdreith, Bryan J. Vogel
6 minute read
April 09, 2013 | Inside Counsel
IP: The failure of venue and joinder reform in patent litigationUntil recently, a patent plaintiff had its choice of bringing suit in any forum in which an accused product was soldin practice, usually any court in the country.
By Jake Holdreith
16 minute read
March 26, 2013 | Inside Counsel
IP: Why do patent cases cost so much to get through trial?It is no secret that patent cases are some of the most expensive cases to get through trial.
By Jake Holdreith
7 minute read
March 12, 2013 | Inside Counsel
IP: Navigating the divideAcademic and noncommercial basic research has always been an engine for innovation, particularly in the areas of medicine and drugs.
By Jake Holdreith, Jamie Kurtz
12 minute read
February 26, 2013 | Inside Counsel
IP: Patent Office trials—A good way to deal with bad patents?Even if theyve never faced a patent infringement lawsuit filed in federal district court, virtually every inside counsel has had to deal with a letter containing notice of alleged patent infringement.
By Jake Holdreith, Cy Morton
12 minute read
February 12, 2013 | Inside Counsel
IP: 5 things to discuss at your first case meeting with outside trial counselAs a trial lawyer who has conducted many complex intellectual property case kickoffs between inside and outside counsel teams, Ive discovered that covering five key questions during that first meeting provides a dependable format for success.
By Jake Holdreith
12 minute read
Trending Stories